Interview with Kerry

Can you tell us about Kerry?
Kerry, through our Sheffield brand, has been in the pharmaceutical industry for over 75 years. We have earned a reputation for reliability and excellence in serving the pharmaceutical and biotechnology markets. We have been involved in every major development in the industry, from our roots as a dairy and lactose producer serving the US market, through to our current position as the world’s most trusted provider of excipient solutions. We are Kerry, leading to better.

How important is the South East Asian market to you? What is the potential?

SEA represents a strong group of rapidly growing economies and substantial populations. With the rise in income levels, government healthcare spending and more people opting for health insurance, the total spend on end products (pharmaceutical) is bound to grow. Similarly, with the advancements in technology, increased number of manufacturers and favorable foreign trade policies being introduced by governments of various SEA countries, exports out of SEA are at a growing pattern. All this translates to huge growth potential for Kerry.

 

What is your organisation’s current level of activity in the South East Asia Pharma market?
Kerry has its regional innovation center in Singapore with sales offices in Bangkok, Malaysia, Vietnam, Singapore, Indonesia and the Philippines. Apart from these, we have an extensive network of distributors across the region who are well-known and connected within the industry. We have a strong market presence and significant amount of market share in Thailand, Indonesia and Malaysia.

 

What are the long-term goals of your company in the Southeast Asia Pharma market?
With the help of our go-to-market strategy, Kerry always focuses on finding the right product and solutions for the end consumers. In the coming years our goal is to position Kerry as a thought leader and complete solution provider for all excipient needs.